Is pharmacological thromboprophylaxis necessary in persons with haemophilia undergoing major orthopaedic surgery?

Autor: Linari S; Center for Bleeding Disorders and Coagulation, Careggi University Hospital, Florence, Italy., Pieri L; Center for Bleeding Disorders and Coagulation, Careggi University Hospital, Florence, Italy., Carulli C; Orthopedic Clinic, Orthopedic Traumatologic Center, Careggi University Hospital, Florence, Italy., Demartis F; Center for Bleeding Disorders and Coagulation, Careggi University Hospital, Florence, Italy., Fjerza R; Center for Bleeding Disorders and Coagulation, Careggi University Hospital, Florence, Italy., Prisco D; Internal Interdisciplinary Medicine Unit, Careggi University Hospital, Florence, Italy., Castaman G; Center for Bleeding Disorders and Coagulation, Careggi University Hospital, Florence, Italy.

Publikováno v: Haemophilia : the official journal of the World Federation of Hemophilia [Haemophilia] 2024 May; Vol. 30 (3), pp. 865-867. Date of Electronic Publication: 2024 Apr 04.

Safe and Successful Surgical Outcome in Persons with Hemophilia A with and without Inhibitors Treated with Emicizumab: A Large, Single Center, Real-World Experience.

Autor: Castaman G; Center for Bleeding Disorders and Coagulation, Department of Oncology, Careggi University Hospital, 50134 Florence, Italy., Linari S; Center for Bleeding Disorders and Coagulation, Department of Oncology, Careggi University Hospital, 50134 Florence, Italy., Pieri L; Center for Bleeding Disorders and Coagulation, Department of Oncology, Careggi University Hospital, 50134 Florence, Italy., Carulli C; Department of Orthopedic Surgery, University Hospital of Florence, 50139 Florence, Italy., Prosperi P; Emergency Surgery Department, Careggi University Hospital, 50134 Florence, Italy., Tonelli P; Department of Surgery and Translational Medicine, University of Florence, 50121 Florence, Italy., Demartis F; Center for Bleeding Disorders and Coagulation, Department of Oncology, Careggi University Hospital, 50134 Florence, Italy., Fjerza R; Center for Bleeding Disorders and Coagulation, Department of Oncology, Careggi University Hospital, 50134 Florence, Italy., Attanasio M; Center for Bleeding Disorders and Coagulation, Department of Oncology, Careggi University Hospital, 50134 Florence, Italy., Coppo M; Center for Bleeding Disorders and Coagulation, Department of Oncology, Careggi University Hospital, 50134 Florence, Italy., Salvianti F; Center for Bleeding Disorders and Coagulation, Department of Oncology, Careggi University Hospital, 50134 Florence, Italy.

Publikováno v: Journal of clinical medicine [J Clin Med] 2023 Mar 16; Vol. 12 (6). Date of Electronic Publication: 2023 Mar 16.

Clinical effect of driver mutations of JAK2, CALR, or MPL in primary myelofibrosis

Autor: Rumi, E, Pietra, D, Pascutto, C, Guglielmelli, P, Martínez Trillos, A, Casetti, I, Colomer, D, Pieri, L, Pratcorona, M, Rotunno, G, Sant'Antonio, E, Bellini, M, Cavalloni, C, Mannarelli, C, Milanesi, C, Boveri, E, Ferretti, V, Astori, C, Rosti, V, Cervantes, F, Barosi, G, Vannucchi, Am, Cazzola, M, Associazione Italiana per la Ricerca sul Cancro Gruppo Italiano Malattie Mieloproliferative Investigators Collaborators Vannucchi AM, Balliu, M, Bartalucci, N, Biamonte, F, Bisognin, A, Bogani, C, Bortoluzzi, S, Bosi, A, Coppe, A, Fanelli, T, Fjerza, R, Loiacono, I, Marchioli, R, Martinelli, S, Masciulli, A, Pancrazzi, A, Paoli, C, Saccoman, C, Spolverini, A, Susini, Mc, Tozzi, L, Azzan, C, Badalucco, S, Balduini, A, Bonetti, E, Campanelli, R, Catarsi, P, Isgrò, Am, Lupo, Ml, Magrini, U, Massa, M, Poletto, V, Villani, L, Ambaglio, I, Bernasconi, P, Casetti, Ic, Catricalà, S, Elena, C, Fugazza, E, Gall, A, Malcovati, L, Ripamonti, F, Rossi, M, Dejana, E, Breviario, F, Corada, M, Erba, Bg, Rambaldi, A, Amaru, A, Barbui, T, Belotti, C, Boroni, C, Ferrari, Ml, Finazzi, G, Finazzi, Mc, Golay, J, Gritti, G, Salmoiraghi, S, Cilloni, Daniela, Campia, V, Carturan, S, Guerrasio, Angelo, Manfredini, R, Bianchi, E, Salati, S, Tagliafico, E, Tenedini, E, Zini, R.

We studied the impact of driver mutations of JAK2, CALR, (calreticulin gene) or MPL on clinical course, leukemic transformation, and survival of patients with primary myelofibrosis (PMF). Of the 617 subjects studied, 399 (64.7%) carried JAK2 (V617F),

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6fcc20185ca75ffed69c01238001098b
https://europepmc.org/articles/PMC4133481/

Tie2 Expressing Monocytes in the Spleen of Patients with Primary Myelofibrosis

Autor: Campanelli, R., Fois, G., Catarsi, P., Poletto, V., Villani, L., Erba, B. G., Maddaluno, L., Jemos, B., Salmoiraghi, S., Guglielmelli, P., Abbonante, V., Di Buduo, C. A., Balduini, A., Iurlo, A., Barosi, G., Rosti, V., Massa, M., Vannucchi, A. M., Balliu, M., Bartalucci, N., Bogani, C., Bosi, A., Calabresi, L., Corbizzi Fattori, G., Fanelli, T., Fjerza, R., Gesullo, F., Mannarelli, C., Merli, L., Pacilli, A., Pancrazzi, A., Paoli, C., Pieri, L., Rotunno, G., Sant'Antonio, E., Bonetti, E., Cazzola, M., Ambaglio, I., Bernasconi, P., Casetti, C. I., Catricala, S., Elena, C., Fugazza, E., Galli, A., Malcovati, L., Milanesi, C., Pascutto, C., Pietra, D., Ripamonti, F., Rossi, M., Rumi, E., Dejana, E., Breviario, F., Corada, M., Malinverno, M., Rambaldi, A., Chioda, G., Ferrari, M. L., Finazzi, G., Finazzi, M. C., Belotti, C., Boroni, C., Amaru, A., Golay, J., Bortoluzzi, S., Bisognin, A., Coppe, A., Saccoman, C., Manfredini, R., Artuso, L., Bernardis, I., Bianchi, E., Montanari, M., Pennucci, V., Prudente, Z., Rontauroli, S., Rossi, C., Ruberti, S., Salati, S., Tagliafico, E., Tenedini, E., Zini, R.

Publikováno v: PLoS ONE, Vol 11, Iss 6, p e0156990 (2016)
PLoS ONE

Primary myelofibrosis (PMF) is a Philadelphia-negative (Ph-) myeloproliferative disorder, showing abnormal CD34+ progenitor cell trafficking, splenomegaly, marrow fibrosis leading to extensive extramedullary haematopoiesis, and abnormal neoangiogenes

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ed4d9b3ebfde475b7177a80862ee66d6
https://doi.org/10.1371/journal.pone.0156990

High frequency of endothelial colony forming cells marks a non-active myeloproliferative neoplasm with high risk of splanchnic vein thrombosis

Autor: Rosti, V, Bonetti, E, Bergamaschi, G, Campanelli, R, Guglielmelli, P, Maestri, M, Magrini, U, Massa, M, Tinelli, C, Viarengo, G, Villani, L, Primignani, M, Vannucchi, Am, Frassoni, F, Barosi, G, Agimm, Investigators, INCLUDING VANNUCCHI AM, Antonioli, E, Bartalucci, N, Biamonte, F, Bogani, C, Bosi, A, Fjerza, R, Malevolti, E, Pancrazzi, A, Pieri, L, Spolverini, A, Susini, Mc, Tozzi, L, Bortoluzzi, Stefania, Bisognin, A, Coppe, A, Marchioli, R, Azzan, C, Badalucco, S, Balduini, A, Carolei, A, Currao, M, Isgrã’, Ma, Lupo, Ml, Magni, V, Cazzola, M, Bernasconi, P, Boggi, S, Elena, C, Gallãœ, A, Malcovati, L, Pascutto, C, Passamonti, F, Pietra, D, Rumi, E, Dejana, E, Corada, M, Giannotta, M, Rambaldi, A, Ferrari, Ml, Finazzi, G, Finazzi, Mc, Magri, M, Quaresmini, G, Montalvo, Ml, Ricci, C, Salmoiraghi, S, Spinelli, O, Amaru, A, Golay, J, Cilloni, D, Arruga, F, Bracco, E, Carturan, S, Gaidano, V, Guerrasio, A, Pradotto, M, Manfredini, R, Bianchi, E, Montanari, M, Salati, S, Tagliafico, E, Tenedini, E, Zini, R.

Publikováno v: PLoS ONE, Vol 5, Iss 12, p e15277 (2010)
PLoS ONE

Increased mobilization of circulating endothelial progenitor cells may represent a new biological hallmark of myeloproliferative neoplasms. We measured circulating endothelial colony forming cells (ECFCs) in 106 patients with primary myelofibrosis, f

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c0592e60ac27a677c654dbebd5d2ade7
https://www.ncbi.nlm.nih.gov/pmc/articles/pmid/21151606/pdf/?tool=EBI